SCHEMBL3045443

SCHEMBL3045443

CCn1c(=O)sc2cc(N)ccc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.54
KDM4E B2RXH2 3/20 0.54
ALDH1A1 P00352 2/20 0.54
GAA P10253 1/20 0.54
GFER P55789 1/20 0.54
CDYL2 Q8N8U2 2/20 0.52
CDYL Q9Y232 2/20 0.52
CBX7 O95931 1/20 0.48
CDY1; CDY1B Q9Y6F8 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.45
MEN1 O00255 1/20 0.45
HPGD P15428 1/20 0.45
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.45
HBB P68871 1/20 0.45
KMT2A Q03164 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
TP53 P04637 1/20 0.44
RAD52 P43351 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15712679 0.83 CDYL2 (0.49) MAPTKDM4EALDH1A1GAAGFER
SCHEMBL28909421 0.80 SIGMAR1 (0.54) MAPTSMN1; SMN2TP53SIGMAR1ADRA2A
SCHEMBL11038312 0.80 MAPT (0.48) MAPTKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL15712345 0.78 L3MBTL1 (0.68) KDM4EALDH1A1GAACDYL2CDYL
SCHEMBL3032915 0.78 CYP1A2 (0.60) MAPTCDYL2CDYLCBX7CDY1; CDY1B
SCHEMBL3035789 0.77 BRPF1 (0.47) MAPTCDYL2CDYLCBX7CDY1; CDY1B
SCHEMBL6333229 0.76 SIGMAR1 (0.53) MAPTTP53SIGMAR1
SCHEMBL4613814 0.76 TP53 (0.56) MAPTKDM4EALDH1A1SMN1; SMN2HPGD
Hydrochloric Acid SCHEMBL7818310 0.76 BRPF1 (0.46) MAPTKDM4EALDH1A1GAAGFER
SCHEMBL513356 0.75 L3MBTL1 (0.64) KDM4EALDH1A1GAASMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645781-B2 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PFIZER INC (US) 2010-01-12 US disclosed
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives THOMAS RICHARD C 2007-01-18 US disclosed
US-7141588-B2 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PFIZER, INC. (US) 2006-11-28 US disclosed
EP-1478629-B1 N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS PHARMACIA & UPJOHN CO LLC (US) 2006-10-11 EP disclosed
US-6919329-B2 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY (US) 2005-07-19 US disclosed
CN-1639135-A N-aryl-2-oxazolidinone-5-amides and derivatives thereof and their use as antibacterial agents UPJOHN CO (US) 2005-07-13 CN disclosed
EP-1478629-A1 N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS PHARMACIA & UPJOHN COMPANY (US) 2004-11-24 EP disclosed
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-07-29 US disclosed
US-20040044052-A1 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-03-04 US disclosed
WO-2003072553-A1 N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATES AND THEIR USE AS ANTIBACTERIALS PHARMACIA & UPJOHN COMPANY (US) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 MAPT 4491/4885KDM4E 905/4885ALDH1A1 956/4885
US-20040044052-A1 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 MAPT 4491/4885KDM4E 905/4885ALDH1A1 956/4885
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 MAPT 4491/4885KDM4E 905/4885ALDH1A1 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.